These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35999268)

  • 1. CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.
    Hsieh CC; Hsu SH; Lin CY; Liaw HJ; Li TW; Jiang KY; Chiang NJ; Chen SH; Lin BW; Chen PC; Chan RH; Lin PC; Yeh YM; Shen CH
    Br J Cancer; 2022 Nov; 127(9):1615-1628. PubMed ID: 35999268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer.
    Yu M; Wang H; Zhao W; Ge X; Huang W; Lin F; Tang W; Li A; Liu S; Li RK; Jiang SH; Xue J
    Theranostics; 2022; 12(9):4386-4398. PubMed ID: 35673560
    [No Abstract]   [Full Text] [Related]  

  • 3. CHK2-mediated regulation of PARP1 in oxidative DNA damage response.
    Hsu PC; Gopinath RK; Hsueh YA; Shieh SY
    Oncogene; 2019 Feb; 38(8):1166-1182. PubMed ID: 30254210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
    Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
    Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
    Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
    Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Casein Kinase 2α Augments Oxaliplatin Resistance in Colorectal Cancer Cells by Increasing ABCE1 Expression.
    Yun CW; Lee JH; Lee SH
    Anticancer Res; 2023 Jun; 43(6):2519-2525. PubMed ID: 37247928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors.
    Pires IM; Ward TH; Dive C
    Br J Pharmacol; 2010 Mar; 159(6):1326-38. PubMed ID: 20128802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307.
    Feng D; He J; Yuan M; Chen Q; Zeng X; Zhou Q; Wu J; Han B
    Biofactors; 2023; 49(6):1158-1173. PubMed ID: 37338025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.
    Cai J; Su L; Luo W
    Bioengineered; 2022 Jun; 13(6):14450-14459. PubMed ID: 35758246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
    Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
    Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.
    Zhang Y; Liu X; Zhang J; Xu Y; Shao J; Hu Y; Shu P; Cheng H
    Aging (Albany NY); 2020 Mar; 12(7):5640-5650. PubMed ID: 32209726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
    Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
    Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
    Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
    Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response.
    Shen X; Zhang Y; Xu Z; Gao H; Feng W; Li W; Miao Y; Xu Z; Zong Y; Zhao J; Lu A
    Cell Death Dis; 2022 Apr; 13(4):303. PubMed ID: 35379798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
    Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
    Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
    Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
    Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
    Xu R; Yin J; Zhang Y; Zhang S
    J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.